CSIMarket
 
Taysha Gene Therapies Inc   (TSHA)
Other Ticker:  
 
 
Price: $2.8700 $-0.19 -6.209%
Day's High: $3.2996 Week Perf: -7.42 %
Day's Low: $ 2.86 30 Day Perf: 17.14 %
Volume (M): 4,212 52 Wk High: $ 3.89
Volume (M$): $ 12,088 52 Wk Avg: $1.65
Open: $3.16 52 Wk Low: $0.50



 Market Capitalization (Millions $) 361
 Shares Outstanding (Millions) 126
 Employees -
 Revenues (TTM) (Millions $) 14
 Net Income (TTM) (Millions $) -215
 Cash Flow (TTM) (Millions $) 130
 Capital Exp. (TTM) (Millions $) 6

Taysha Gene Therapies Inc
Taysha Gene Therapies Inc is a clinical-stage gene therapy company focused on discovering, developing, and commercializing potential curative treatments for severe genetic disorders. Founded in 2020, the company utilizes its proprietary technology platform to develop transformative gene therapies for various neurological and lysosomal storage disorders. Taysha aims to address the underlying genetic cause of these disorders by delivering corrected genes or gene-modifying technologies to patients. The company is committed to advancing the field of gene therapy and improving the lives of patients suffering from debilitating genetic diseases.


   Company Address: 3000 Pegasus Park Drive Dallas 75247 TX
   Company Phone Number: 612-0000   Stock Exchange / Ticker: NASDAQ TSHA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Taysha Gene Therapies: Advancing Rett Syndrome Clinical Program Amid Revenue Challenges

Published Thu, Feb 29 2024 1:00 PM UTC

In recent updates revealed by Taysha Gene Therapies, the company announces significant progress in its TSHA-102 Clinical Program for Rett Syndrome. Additionally, the company reports a substantial decrease in revenue for the same period. This article aims to outline the facts surrounding these updates and assess their impact on Taysha Gene Therapies.Taysha Gene Therapies' TSH...

Management Announcement

Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs: An Effort to Enhance Development Potential

Published Thu, Feb 15 2024 9:01 PM UTC


Introduction
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a prominent clinical-stage gene therapy company specializing in AAV-based gene therapies for central nervous system (CNS) monogenic diseases, has recently shared an update on its deprioritized pipeline programs. The company aims to provide further support and opportunities for the potential development of thes...

Clinical Study

Taysha's Groundbreaking Milestone: Dosing TSHA-102 in Pediatric Patient for Rett Syndrome Trial

Published Wed, Jan 10 2024 1:01 PM UTC

In a significant breakthrough for biotechnology, Taysha Gene Therapies has announced that it has successfully dosed a pediatric patient with TSHA-102 under its Phase 1/2 REVEAL trial for Rett Syndrome. As it continues to deliver impressive clinical advancements in gene therapies, this milestone symbolizes a beacon of hope for the medical community and patients suffering from...

Shares

Taysha Gene Therapies Grants Stock Option to New Senior Vice President

Published Fri, Jan 5 2024 1:00 PM UTC


Date: January 5, 2024
In a recent press release, Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a leading clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for central nervous system diseases, announced that it has granted Meredith Schultz, M.D., M.S., an option to purchase 257,700 shares of the company's common stoc...

Clinical Study

Taysha Gene Therapies Expands Breakthrough Rett Syndrome Trial to Include Adolescents, While Revenue Growth Lags Behind Competitors

Published Wed, Nov 29 2023 1:00 PM UTC

Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial for Rett Syndrome Patients, Including Adolescents
Health Canada has authorized Taysha Gene Therapies' protocol amendment to expand eligibility for the REVEAL Phase 1/2 adult trial in Canada. This expansion now includes patients aged 12 and older with stage four Rett syndrome. This develo...






 

Taysha Gene Therapies Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com